MedTrace Logo

Tau Networks in Psychotic Alzheimer's Disease

NCT05847192 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 91

Last updated 2026-04-08

No results posted yet for this study

Summary

This research project aims to understand the brain mechanisms behind the manifestation of psychotic symptoms in Alzheimer´s disease (AD), and nature of the unique relationship with tau pathology. Amongst the cognitive manifestations of psychosis are impairments related to frontal circuits (social cognition, working memory and executive function deficits). The investigator's previous work suggests a role of tau pathology (one of the hallmarks of AD neuropathology) in the manifestation of psychosis in AD. However, the cerebral mechanisms that underly this association remain poorly understood. The overarching aim of the study is is to investigate the mechanisms by which tau network pathology may promote the presentation of psychosis in AD.

Conditions

  • Alzheimer Disease
  • Alzheimer Disease With Delusions
  • Alzheimer Disease With Psychosis

Interventions

DIAGNOSTIC_TEST

[18F]-PI2620 PET scan

The PET scan will measure the regional distribution of tau aggregation in AD patients with and without psychosis compared to Cognitively Unimpaired Healthy participants with the PET radiotracer \[18F\]-PI2620.

Sponsors & Collaborators

  • Northwell Health

    lead OTHER

Principal Investigators

  • Jeremy Koppel, MD · Northwell Health

Eligibility

Min Age
65 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-04-13
Primary Completion
2028-12-31
Completion
2029-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05847192 on ClinicalTrials.gov